40th week of 2014 patent applcation highlights part 51 |
Patent application number | Title | Published |
20140294929 | COMPOSITIONS FOR DELIVERY OF CARGO SUCH AS DRUGS PROTEINS AND/OR GENETIC MATERIALS - Compositions and methods for delivery of cargo molecules to a patient or subject in need thereof include a proteoliposome carrier vehicle that incorporates an RLIP76 protein and contains the cargo molecule. The vehicle effectively delivers the cargo molecule systemically throughout the tissues of the body including into the central nervous system. | 2014-10-02 |
20140294930 | STREPTOCOCCAL GlcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM - In alternative embodiments, the invention provides vaccines, pharmaceutical compounds and formulations for diagnosing, preventing, treating or ameliorating Group A | 2014-10-02 |
20140294931 | METHOD AND COMPOSITION OF THYROID HORMONE ANALOGUES AND NANOFORMULATIONS THEREOF FOR TREATING ANTI-INFLAMMATORY DISORDERS - Thyroid hormone antagonists and their nanoparticle formulations (Nanotetrac™ or Nanotriac™) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines. Thyroid hormone antagonists inhibit expression in tumor cells of cytokine genes, e.g., specific interleukins, and chemokine genes, such as fractalkine (CX3CL1), and chemokine receptor genes (CX3CR1) that are targets in the development of inflammation-suppressant drugs. This application discloses a novel composition of Tetra or Tri-iodothyroacetic acid (tetrac or triac), other thyroid partial agonists or antagonists and their nanoparticle formulations conjugated to polymers and encapsulating non-steroidal anti-inflammatory, anti-inflammatory glucocorticoids, and/or polyphenols for the management of various acute and chronic inflammatory disorders ranging from neurological, vascular, and musculoskeletal disorders. | 2014-10-02 |
20140294932 | TEMPERATURE SENSITIVE LIPOSOME INCLUDING CATIONIC LIPID AND USE THEREOF - Provided are a liposome including a cationic lipid, a pharmaceutical composition for the delivery of anionic drugs, and a method for delivering anionic drugs to a target site. | 2014-10-02 |
20140294933 | COMPOSITION FOR DELIVERY OF ANGIOGENESIS INDUCING MOLECULE AND ARTIFICIAL TISSUE PREPARED BY THE COMPOSITION - A composition for delivery of an angiogenesis inducing agent, including a temperature-sensitive liposome, a vascular cell-specific antibody, and an angiogenesis inducing agent, a tissue culture obtained using the composition, an artificial tissue including the tissue culture, and a method for preparing an artificial tissue are provided. | 2014-10-02 |
20140294934 | CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS - Here described are compounds of formula I: | 2014-10-02 |
20140294935 | VACCINE COMPOSITION - The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are | 2014-10-02 |
20140294936 | Compositions And Methods For Inhibiting Expression Of The HAMP Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition. | 2014-10-02 |
20140294937 | LIPID COMPOSITIONS FOR NUCLEIC ACID DELIVERY - The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol. | 2014-10-02 |
20140294938 | MRNA THERAPY FOR FABRY DISEASE - Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies. | 2014-10-02 |
20140294939 | PULMONARY DELIVERY OF MRNA - Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies. | 2014-10-02 |
20140294940 | MRNA THERAPY FOR UREA CYCLE DISORDERS - Disclosed herein are compositions and methods of modulating the expression of gene or the production of a protein by transfecting target cells with nucleic acids. The compositions disclosed herein demonstrate a high transfection efficacy and are capable of ameliorating diseases associated with protein or enzyme deficiencies. | 2014-10-02 |
20140294941 | ANTI-ANGIOGENIC COMPOSITIONS AND THERAPEUTIC APPLICATIONS THEREOF - There is described the use of the Human herpesvirus type 6 (HHV-6) U94 gene and its product, the protein Rep, expression vectors and pharmaceutical compositions suitable for the delivery of the U94 gene or the protein encoded therefrom to the therapeutic sites, to inhibit angiogenic and lymphangiogenic processes in a subject in need thereof. | 2014-10-02 |
20140294942 | ANTIVIRAL PEPTIDES EFFECTIVE AGAINST HEPATITIS C VIRUS - In certain embodiments this invention provides novel antiviral peptide(s) that are effective against positive sense RNA viruses that have an internal ribosome entry site (IRES). The peptide(s) can be used to inhibit propagation of such viruses and thereby provide a effective modality for the treatment of infections such as hepatitis C, and the like. | 2014-10-02 |
20140294943 | METHODS OF USING MICRORNA 195 IN PROVIDING NEUROPROTECTION - The invention relates to a method for providing neuroprotection comprising administering to a subject an effective amount of a miRNA or a variant thereof. By providing neuroprotection, or ischemic stroke can be prevented and/or treated. | 2014-10-02 |
20140294944 | MICROENCAPSULATION OF OXYGEN LIBERATING REACTANTS - There is provided a composition for the delivery of oxygen having microencapsulated peroxide and microencapsulated catalyst that liberate oxygen upon sufficient contact with each. The components may be stored separately or together until use. Upon mixing, oxygen is liberated. The composition can be used for wound healing or for cosmetic applications to deliver oxygen to the skin to help skin elasticity and retard the effects of aging. | 2014-10-02 |
20140294945 | METHODS AND DEVICES FOR FORMING TREATMENT AGENT CARRIERS - A method is described including passing a solution having a biodegradable polymer, a solvent and a treatment agent through an electrocharged nozzle to form particles encapsulating the treatment agent. The particles emitted from the electrocharged nozzle may be exposed to a charge opposite that of the nozzle. The particles may be deposited in a collection assembly comprising a liquid phase. A further method including combining a biodegradable polymer, a solvent and a treatment agent to form a solution, electrodepositing the solution in a particle form wherein the particles encapsulate the treatment agent in a collection assembly comprising a liquid phase and mixing the particles with a bioerodable material capable of forming a gel is described. An apparatus having an electrocharged nozzle, a grounded electrode having an opposite charge to that of the nozzle and a collection assembly comprising a liquid phase is further disclosed. | 2014-10-02 |
20140294946 | PHARMACEUTICAL COMPOUNDS - Fused pyrimidines of formula (I): | 2014-10-02 |
20140294947 | TAMPER RESISTANT IMMEDIATE RELEASE FORMULATIONS - Disclosed in certain embodiments is an oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising a gelling agent; (ii) an optional barrier layer encompassing the core; (iii) an active layer comprising a drug susceptible to abuse encompassing the core or barrier layer; and (iv) an optional controlled release excipient; wherein the dosage form provides an immediate or controlled release; and wherein the viscosity of the dosage form mixed with from about 0.5 to about 10 ml of an aqueous liquid is unsuitable for parenteral or nasal administration. | 2014-10-02 |
20140294948 | COMPOSITION AS AUXILIARY MEANS FOR ORAL MEDICATION - The invention relates in one aspect to a composition, specifically a jelly, the use of which composition as an auxiliary means is to ease the taking of oral medication in solid form, which composition comprises iota-carrageenan as a jellifying agent and citric acid as a salivating agent, characterized in that the composition further comprises maltodextrin. In another aspect, the composition comprises a calcium sequestrant for adjusting Ca-ion activity of the composition. In one embodiment, the composition comprises iota-carrageenan in 0.7-1.0% in mass, citric acid in 0.06-0.07% in mass, maltodextrin in 1.5% in mass, all relative to the total mass of the composition, and an amount of a calcium sequestrant such that the Ca-ion activity of the composition is between 20 ppm and 80 ppm. | 2014-10-02 |
20140294949 | VERMIN POISON - Use of an orally or nasally available formulation of Tretazicar for poisoning vermin. An orally available or nasally available formulation of Tretazicar, wherein in the orally available formulation the Tretazicar is protected from acid hydrolysis, and provided that the formulation is not solid Tretazicar in a gelatin capsule. A formulation of Tretazicar in which the Tretazicar is protected from acid hydrolysis, wherein the formulation is present in a liquid form. A combination of Tretazicar and bait. A method of poisoning vermin comprising making available to the vermin an orally or nasally available formulation of Tretazicar and allowing the vermin to ingest or inhale the formulation of Tretazicar. | 2014-10-02 |
20140294950 | METHODS OF TREATING OBESITY IN RESPONDER AND NON-RESPONDER POPULATIONS - The disclosed embodiments relate to, dosing regimens for the administration of topiramate, optionally in combination with one or more sympathomimetic agents such as phentermine. The dosing regimens can, for example, limit the exposure of subjects to topiramate, identify subjects who are unlikely to obtain a benefit from treatment with escalating dosages of topiramate (with or without the sympathomimetic agent, such as phentermine), or both, thereby reducing or eliminating harmful or intolerable side effects in subjects who are unlikely to respond to treatment and maximizing the therapeutic benefits from treatment in subjects who do respond. | 2014-10-02 |
20140294951 | Oral formulations mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and T2D - The invention provides pharmaceutical compositions, methods for the treatment of and related diagnostics and computer-implementable systems that relate to, the treatment of a variety of metabolic syndromes, including hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states. In an additional aspect of the invention, compositions and methods of treatment are calibrated to the ileal brake response to surgical intervention e.g. RYGB, as both activate the ileal brake, which acts in the gastrointestinal tract and the liver of a mammal to control metabolic syndrome manifestations and thereby reverse or ameliorate the cardiovascular damage (atherosclerosis, hypertension, lipid accumulation, and the like) resulting from progression of metabolic syndrome. The net benefit is the potential to treat all of the common manifestations of metabolic syndrome, including T2D and obesity, with one medicament, which contains glucose as an activation agent for the ileal brake. The ileal brake is the controller for progression of metabolic syndrome, and both RYGB surgery and the oral formulation act beneficially on the metabolic syndrome manifestations via this pathway. Disclosed as well are combination medicaments that act synergistically on the ileal brake and the manifestations of metabolic syndrome. In other aspects, the invention provides ileal brake hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in selective control of appetite, stabilizing blood glucose and insulin levels, and treating gastrointestinal disorders in a similar manner to RYGB surgery, but having at least 20% of the potency to stimulate the hormonal response of the ileal brake of humans. | 2014-10-02 |
20140294952 | DISSOLVABLE MEDICATION ADMISISTRATION BAG AND METHOD OF USING THE SAME - A dissolvable medication administration bag for the safe and effective crushing and administration of medication to patients who have difficulty swallowing pills is disclosed herein. In some embodiments, the dissolvable medication administration bag is constructed in accordance with a pill crusher pouch embodiment into which a pill is placed prior to being crushed and subsequently the whole of pouch and the crushed pill contents are dissolved into a liquid, e.g. a beverage, as a means of reducing health hazards associated with current pill crushing practices such as inadvertent direct contact and aerosolization with subsequent inhalation of the crushed medication. In other embodiments, the dissolvable medication administration bag is constructed in accordance with a pre-packaged medicine dosage administration bag embodiment wherein the whole of the pre-packaged bag and its powdered or liquid form medication contents are dissolved into a liquid with no need for crushing. | 2014-10-02 |
20140294953 | Abuse-Resistant Formulations - The disclosure relates to a sustained-release oral dosage form for once-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydromorphone. The dosage form can have a release profile such that 16 hours following administration, less than about 85 percent of the hydromorphone is released. In addition, the dosage form may have alcohol and/or crush resistance. | 2014-10-02 |
20140294954 | MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION - Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a first layer and a second layer. The core comprises a superabsorbent material (for example, polycarbophil), and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to create a hard gel that traps the microparticles. The hard gel and microparticles provide controlled release of the pharmaceutically active agent. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof. | 2014-10-02 |
20140294955 | MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION - Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a superabsorbent material. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material creates a hard gel that traps the microparticles. The hard gel and microparticles provide controlled release of the pharmaceutically active agent. | 2014-10-02 |
20140294956 | GASTRIC RETENTIVE EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS - The present disclosure provides extended release pharmaceutical compositions comprising an opioid and an additional active pharmaceutical ingredient, wherein the composition exhibits gastric retentive properties which are achieved by a combination of a physical property of the composition and release of the opioid, wherein upon administration to a subject, the composition has at least one pharmacokinetic parameter that differs by less than about 30% when the subject is in a fasted state as compared to a fed state. | 2014-10-02 |
20140294957 | NICLOSAMIDE FOR THE TREATMENT OF CANCER METASTASIS - The invention relates to niclosamide and derivates thereof, which effectively inhibit transcription of the S100A4 gene, resulting in inhibition and/or reduction of S100A4-induced cell motility, invasiveness, metastasis and proliferation of human cancer cells. | 2014-10-02 |
20140294958 | LUBRICIOUS COATINGS - The present invention relates to lubricious coatings comprising an ionomer and a hydrophilic polymer wherein the ionomer is cross-linked using a suitable cross-linking agent, and optionally also conventional excipients, such as a surfactant, a plasticizer and/or a filler. The invention also relates to pharmaceutical products covered by such lubricious coatings, compositions for preparing these lubricious coatings and a method for providing pharmaceutical products with these lubricious coatings. | 2014-10-02 |
20140294959 | Pharmaceutical Composition of Rosuvastatin Calcium - The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture. | 2014-10-02 |
20140294960 | IMPLANTABLE MODULAR HYDROGEL FOR SALIVARY GLAND RESTORATION - Implantable modular hydrogels to aid in salivary gland restoration and associated methods are provided. In one embodiment, the present disclosure provides for a hydrogel network comprising: a hyaluronic acid macromer crosslinked with a multiblock copolymer. | 2014-10-02 |
20140294961 | HEPATIC PROTECTION AGENT CONTAINING EGGSHELL MEMBRANE AND PHARMACEUTICAL COMPOSITION, FOOD ADDITIVE AND FOOD USING THE SAME - The hepatoprotective agent contains eggshell membrane-containing fine powder, wherein the eggshell membrane-containing fine powder is eggshell membrane-containing fine powder having a volume mean particle diameter of 6 μm or less and/or eggshell membrane-containing fine powder having a volume maximum particle diameter of 20 μm or less. When fed with feed including eggshell membrane-containing fine powder with these values (sample C), the liver injury group (CCl | 2014-10-02 |
20140294962 | METHOD OF PREPARING POLYMORPHIC PURE FORM A OF BAZEDOXIFENE ACETATE - The present invention provides a reliable process for the preparation of polymorphic pure form A of Bazedoxifene x acetate. In addition, the present invention relates to a process of wet granulation of polymorphic pure form A of Bazedoxifene x acetate. The present invention also relates to pharmaceutical compositions comprising polymorphic pure form A of Bazedoxifene x acetate as well as to the use of cyclic ethers for the preparation of such pharmaceutical composition. | 2014-10-02 |
20140294963 | Novel Gold-Platinum Based Bi-Metallic Nanocrystal Suspensions, Electrochemical Manufacturing Processes Therefor and Uses for the Same - The present invention relates to novel gold-platinum based bi-metallic nanocrystal suspensions that have nanocrystal surfaces that are substantially free from organic or other impurities or films associated with typical chemical reductants/stabilizers and/or raw materials used in nanoparticle formation processes. Specifically, the surfaces are “clean” relative to the surfaces of metal-based nanoparticles made using chemical reduction (and other) processes that require organic (or other) reductants and/or surfactants to grow (and/or suspend) metal nanoparticles from metal ions in a solution. The invention includes novel electrochemical manufacturing apparatuses and techniques for making the bi-metallic nanocrystal suspensions. The techniques do not require the use or presence of chlorine ions/atoms and/or chlorides or chlorine-based materials for the manufacturing process/final suspension. The invention further includes pharmaceutical compositions thereof and the use of the bi-metallic nanocrystals or suspensions or colloids thereof for the treatment or prevention of diseases or conditions for which metal-based therapy is already known, including, for example, for cancerous diseases or conditions. | 2014-10-02 |
20140294964 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH DACARBAZINE NANOEMULSIONS - A uniform microfluidized nanoemulsion is disclosed containing an anti-cancer agent, such as dacarbazine. The microfluidized nanoemulsion improves the combination's cell membrane permeability by at least four-fold over conventional nanoemulsion compositions, which significantly increases the intracellular concentration of anticancer agents. As a nanoemulsion, dacarbazine has a greater anti-cancer efficacy than when applied as a free solution. | 2014-10-02 |
20140294965 | COMPOSITIONS AND METHODS FOR EXFOLIATING PARTICLES - Various embodiments provide compositions for exfoliating particles and methods for their manufacture. In one exemplary embodiment, the exfoliating particles may comprise a derivative of a botanically-sourced emollient, stearyl stearate, and at least one of: candelilla wax, is bran wax, sunflower wax, jojoba esters, carnauba wax, bees wax, corn wax, a saturated wax-ester, castor wax, ouricury wax, hydrogenated lanolin, and a hydrogenated triglyceride wax, Exemplary methods for producing the exfoliating particles may comprise melting, combining, and/or homogenizing the components of the exfoliating particles and cooling the resultant mixture in a process to form particles of a desired shape and/or size. The exfoliating particles may be for topical use and may be stable in personal care compositions. | 2014-10-02 |
20140294966 | STABLE NANOCOMPOSITION COMPRISING DOCETAXEL, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT - A nanoparticulate composition is disclosed for the targeted therapeutic treatment of tumours. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked to either the polycation/modified polycation or the polyanion/modified polyanion, or both or to the surface of the nanoparticle; (ii) an active compound selected from the group of docetaxel and its pharmaceutically acceptable salts and derivatives especially its hydrates, especially docetaxel trihydrate and docetaxel trihydrate monohydrochloride; and optionally (iii) at least one complexing agent, a metal ion and a stabilizer/formulating agent, or a PEGylating agent. The present invention furthermore relates to a process for the preparation of the above-mentioned composition, the therapeutic uses thereof, and pharmaceutical compositions containing the nanocomposition according to the invention. | 2014-10-02 |
20140294967 | STABLE NANOCOMPOSITION COMPRISING PACLITAXEL, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT - A nanoparticulate composition is disclosed for the targeted therapeutic treatment of tumours. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked to either the polycation/modified polycation or the polyanion/modified polyanion, or both or to the surface of the nanoparticle; (ii) paclitaxel as active compound; and optionally (iii) at least one complexing agent, a metal ion and a stabilizer/formulating agent or a PEGylating agent. The invention furthermore relates to a process for the preparation of the above-mentioned composition, the therapeutic uses thereof, and pharmaceutical compositions containing the nanocomposition according to the invention. | 2014-10-02 |
20140294968 | POLYACRYLATE-BASED ACTIVE COMPOUND-COMPRISING PARTICLES - The invention relates to novel polyacrylate-based active compound-comprising particles which bind to hair, and to the use of these particles for preparing medicaments, in particular for veterinary medicine. The particles comprise uncharged and cationic polyacrylate and are at most 10 um big. | 2014-10-02 |
20140294969 | Method and formulation for inhalation - This invention relates to drug delivery and in particular to the delivery of biologically active agents in the form of dry powders for inhalation. The invention also relates to methods for preparing such dry powder formulations and methods for their use. | 2014-10-02 |
20140294970 | STABILIZED PHARMACEUTICAL SUB-MICRON SUSPENSIONS AND METHODS OF FORMING SAME - The present invention is directed to a pharmaceutical submicron suspension and a method of forming the submicron suspension. The submicron suspension is useful for delivery of relatively hydrophobic and/or low solubility therapeutic agent. The submicron suspension and method of forming the submicron suspension typically employ a polymeric material that aids in preventing aggregation of the therapeutic agent. | 2014-10-02 |
20140294971 | CANCER CELL-INHIBITING CERAMIC, PROCESS FOR PRODUCING CANCER CELL-INHIBITING CERAMIC, METHOD FOR TREATING BONE TUMOR, AND USE OF BETA-TRICALCIUM PHOSPHATE POROUS GRANULES WITH PARTICLE SIZE OF 1 TO 10 MICROMETER - Proliferation of cancer cells is effectively inhibited. Provided is a cancer cell-inhibiting ceramic containing a β-tricalcium phosphate porous granule with a particle size of 1 to 10 μm. The β-tricalcium phosphate porous granule is taken up into cancer cells at an affected area and have an effect of inhibiting proliferation of a cancer tissue. The β-tricalcium phosphate porous granule with a particle size of 1 to 10 μm can be used to more effectively inhibit the proliferation of the cancer cells. | 2014-10-02 |
20140294972 | Oral Suspension - A liquid pharmaceutical composition for use in the treatment of acute lymphoblastic leukaemia (ALL) comprising 6-mercaptopurine or a salt, hydrate or solvate thereof and a pharmaceutically-acceptable excipient, wherein the composition is a suspension for oral administration, a kit of parts for the accurate dosing and administration of the liquid pharmaceutical composition, and a method for the treatment of ALL in a human patient comprising administration of a therapeutically effective amount of the liquid pharmaceutical composition. | 2014-10-02 |
20140294973 | PHARMACEUTICAL COMPOSITIONS OF HYDROPHOBIC CAMPTOTHECIN DERIVATIVES - The present invention provides a pharmaceutical composition comprising at least one hydrophobic camptothecin derivative or a pharmaceutically acceptable salt of said derivative and a polyethylene glycol (PEG) conjugated phospholipid. Also provided is a method to inhibit cancer cells in a subject in need thereof by administering the pharmaceutical composition of the present invention. | 2014-10-02 |
20140294974 | COSMETIC COMPOSITION - The invention relates to a cosmetic composition comprising an emulsion comprising hydrophobically modified particles, amino functionalized silicone and water; the cosmetic composition further comprising a moisturizing agent and at least one component selected from the group consisting of vitamin, anti-dandruff agent and surfactant, wherein the composition comprises at least a vitamin or anti-dandruff agent. The invention further relates to a method of treating a skin condition comprising the step of topically applying to the skin the cosmetic composition of the invention. | 2014-10-02 |
20140294975 | SOLID ANTI-SUN COMPOSITION BASED ON LIPOPHILIC ORGANIC UV SCREENING AGENT AND AEROGEL PARTICLES OF HYDROPHOBIC SILICA - The present invention thus relates to a solid composition, in particular in the form of a loose or compact powder, comprising, in a cosmetically acceptable medium: a) at least one pulverulent phase; b) at least one lipophilic organic UV screening agent characterized in that the pulverulent phase comprises at least aerogel particles of hydrophobic silica exhibiting a specific surface per unit of weight (S | 2014-10-02 |
20140294976 | COSMETIC PREPARATION COMPRISING PULVERIZED HYDROPHILIC SUBSTANCES - A substance, which is in principle insoluble in a cosmetic or dermatological anhydrous preparation is converted into a powdery product by absorption onto a carrier, the powdery product being soluble in the preparation. The anhydrous preparations comprise one or more hydrophilic substances or substance mixtures which are liquid, pasty at room temperature and/or meltable up to a temperature of 150° C. and which are absorbed on one or more particulate carriers. The hydrophilic substance or substance mixture in itself is insoluble or sparingly soluble in the preparation and the carriers are characterized by a particle size ranging from 5 nm to 2 mm, a tamped density of between 50 kg/m | 2014-10-02 |
20140294977 | Radiation-Sterilized Biodegradable Drug Delivery Composition - The present disclosure is directed to a method of making a composition by combining a vehicle, e.g., a single phase vehicle, and an insoluble component comprising a beneficial agent, and sterilizing the composition using ionizing radiation prior to use, wherein the beneficial agent is stable following exposure to a sterilizing dose of ionizing radiation. Related compositions and methods are provided. | 2014-10-02 |
20140294978 | CATIONIC LIPID - The present invention provides a cationic lipid and the like. The cationic lipid is for delivering a medicament containing a cationic lipid which facilitates the introduction of a nucleic acid into a cell or the like, and is represented by formula (I). | 2014-10-02 |
20140294979 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REGULATION OF G- AND/OR GC-RICH NUCLEIC ACID EXPRESSION - Methods and pharmaceutical compositions for regulations of Guanosine- (G-) and/or Guanosine-cytosine-rich (GC-rich) nucleic acid expressions are provided. The methods include a step of interacting the G- and/or GC-rich region of the nucleic acid with thalidomide, and the pharmaceutical compositions include the thalidomide and a pharmaceutical carrier. | 2014-10-02 |
20140294980 | SUSTAINED RELEASE PARTICLE FORMULATIONS - Particles for delivery of active ingredients formed from an active ingredient and a hydrophobic matrix, as well as methods for making such particles. | 2014-10-02 |
20140294981 | CARBON ENCAPSULATED TRANSITION METAL OXIDE NANOCOMPOSITE, A METHOD FOR ITS PREPARATION AND ITS USE IN LI-ION BATTERIES - A nanocomposite includes carbon-encapsulated transition metal oxide nanoparticles. The carbon-encapsulated transition metal oxide nanoparticles comprise a transition metal oxide core having a diameter of from 5 nm to 50 nm covered by a graphitic coating having a thickness of from 1 nm to 5 nm. | 2014-10-02 |
20140294982 | NANOPARTICLE COMPOSITIONS FOR GENERATION OF REGULATORY T CELLS AND TREATMENT OF AUTOIMMUNE DISEASES AND OTHER CHRONIC INFLAMMATORY CONDITIONS - The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells, and for the in vivo generation of regulatory T cells, notably CD4+CD25+FOXP3+ regulatory T cells (Treg). The invention provides pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory T cells. The nanoparticles used in the invention comprise a) a micelle comprising an amphiphilic polymer rendering the nanoparticle water-soluble, and b) a peptide comprising at least one T cell epitope associated with the outside of the micelle. The micelle may or may not comprise a solid hydrophobic core. | 2014-10-02 |
20140294983 | STABLE NANOCOMPOSITION COMPRISING DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT - A nanoparticulate composition for the targeted therapeutic treatment of tumours. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked to either the polycation/modified polycation or the polyanion/modified polyanion, or both, or to the surface of the nanoparticle; (ii) an active compound selected from the group of doxorubicin and its pharmaceutically acceptable salts, especially hydrochloride; and optionally (iii) at least one complexing agent, a metal ion, a stabilizer/formulating agent, or a PEGylating agent. The present invention furthermore relates to a process for the preparation of the above-mentioned composition, the therapeutic uses thereof, and pharmaceutical compositions containing the nanocomposition according to the invention. | 2014-10-02 |
20140294984 | COMPACTED RUMEN PROTECTED NUTRIENT PELLETS AND METHOD OF MANUFACTURE - A process for producing a compacted rumen-protected nutrient pellet and the resultant pellet. The process includes the steps of (i) blending a C4-24 fatty acid and a biologically active ingredient to form solid central core particles, (ii) compacting the core particles to form pellets, and (iii) sequentially coating the pellets with an organic solvent and a fatty acid alkali metal or alkaline earth metal salt. | 2014-10-02 |
20140294985 | BONE PASTES COMPRISING BIOFUNCTIONALIZED CALCIUM PHOSPHATE CEMENTS WITH ENHANCED CELL FUNCTIONS FOR BONE REPAIR - The invention provides injectable, biofunctional agent-containing calcium phosphate cement bone pastes for bone tissue engineering, and methods of making and using the same. | 2014-10-02 |
20140294986 | Microsphere Drug Delivery System for Sustained Intraocular Release - Disclosed are biodegradable microspheres between 40 μm and 200 μm in diameter that are effectively retained in the anterior chamber of the eye without producing hyperemia. The microspheres generally contain a drug effective for the treatment of an ocular condition and include a biodegradable polymer matrix that can provide for the sustained (>7 day) release of the drug following administration to the anterior chamber of the eye. Methods for making and using the microspheres to treat an ocular condition are also disclosed. | 2014-10-02 |
20140294987 | PLANT DERIVED SEED EXTRACT RICH IN ESSENTIAL FATTY ACIDS DERIVED FROM PERILLA SEED: COMPOSITION OF MATTER, MANUFACTURING PROCESS AND USE - A composition of matter comprises a shelf stable, super critical, CO | 2014-10-02 |
20140294988 | SKIN TREATMENT FORMULA FOR PSORIASIS - A topical treatment is disclosed for combating psoriasis comprising a combination of coconut oil, cocoa butter, olive oil, beeswax and rose oil. Versions of the formula also may contain neem oil, jojoba oil and/or salicylic acid. The formula is topically applied to the skin after a washing and can be used as preventative measure as well as treatment for an acute flare up. | 2014-10-02 |
20140294989 | COPPER-AND-TITANIUM-CONTAINING COMPOSITION AND PRODUCTION METHOD THEREFOR - The Cu- and Ti-containing composition of the present invention contains titanium oxide including rutile-crystal-type titanium oxide, and a divalent copper compound, wherein the rutile-crystal-type titanium oxide exhibits the most intense diffraction peak attributed to rutile-type titanium oxide having a full width at half maximum of 0.65° or less, in a Cu—Kα line X-ray diffraction pattern, which is obtained by plotting intensity of diffraction line with respect to diffraction angle 2θ. The composition exhibits excellent anti-viral property under light and in the dark, and excellent organic compound degradability under light. | 2014-10-02 |
20140294990 | THROAT GARGLE TABLET AND METHOD OF USE THEREOF - An anhydrous composition is provided. The anhydrous composition may be a tablet configured to dissolve in water, the tablet including Vitamin C (as ascorbic acid), Vitamin E (as dl-alpha-tocopheryl acetate), Magnesium (as magnesium sulfate and magnesium oxide), Zinc (as zinc sulfate), Chloride (as sodium chloride), Sodium (as sodium chloride, sodium bicarbonate and Sodium carbonate), Potassium (as potassium bicarbonate), Salt (as sodium chloride), Aloe Vera, Chamomile (as matricaria recutita), Honey, and/or Stevia Leaf extract. The anhydrous composition may further comprise Citric Acid, Sorbitol, Natural flavor, Wheat Germ Oil, and/or Magnesium Oxide. | 2014-10-02 |
20140294991 | MEDICAMENT FOR TREATING ANTERIOR EYE DISEASE COMPRISING REBAMIPIDE AND A TEAR-RETAINING AGENT - The present invention provides a combination of rebamipide and a tear-retaining agent as a medicament for the treatment of anterior eye diseases. | 2014-10-02 |
20140294992 | HIGHLY STABLE ELECTROLYTIC WATER WITH REDUCED NMR HALF LINE WIDTH - Electrolytic acid or alkaline water having a NMR half line width using 17O of from about 45 to less than 51 Hz, and an oxide reduction potential of from −1000 to +200 mV, or from +600 to +1300 mV, topical compositions that contain such water, uses for such water to hydrate skin, deliver drugs and treat various skin and mucosal conditions, and methods and apparatus for manufacturing the water. | 2014-10-02 |
20140294993 | METHOD FOR TREATMENT OF MESOTHELIOMA - The present invention provides that Ras-like, estrogen-regulated, growth inhibitor (RERG) is a malignant mesothelioma biomarker of clinical course and treatment sensitivity and, itself a target for mesothelioma treatment. A low RERG level in a mesothelioma subject indicates poor prognosis. Analyzing RERG expression level along can help mesothelioma patients make treatment choices. Furthermore, mesothelioma can be treated by modulating RERG activity, for example, with treatment with estrogen or estrogen-like agents. | 2014-10-02 |
20140294994 | PHARMACEUTICAL COMPOSITION FOR ELIMINATION OF CANCER STEM CELLS - The preset invention relates to use of antipsychotic phenothiazine derivative for eliminating cancer stem cells (CSCs) and/or preventing a cancer. The invention also provides a pharmaceutical composition for treating a cancer, and/or preventing or delaying cancer recurrence comprising trifluoperazine and an anti-cancer drug, such as gefitinib or cisplatin. | 2014-10-02 |
20140294995 | Lozenge for treating sore throat, hoarseness and associated dry cough, and inflammatory diseases of the oral and pharyngeal cavity - The present invention relates to a pharmaceutical formulation containing a combination of (a) at least one astringent active substance and (b) at least one mucilaginous drug and the use thereof for the prevention or treatment of inflammatory diseases of the oropharyngeal region and for the treatment of painful irritations of the mucosa in the oropharyngeal region and associated irritable cough. | 2014-10-02 |
20140294996 | ONE OR MORE OF VIGNA MARINA, COCOS NUCIFERA L. OR TERMINALIA CATAPPA L. EXTRACTS FOR TREATING WOUNDS, SKIN DISORDERS AND HAIR LOSS - Biologically active extracts of one or more | 2014-10-02 |
20140294997 | COMPOSITION AND USE OF A FORMULATION TO INCREASE THE RATIO OF GASTROINTESTINAL MICROBIOTA IN PHYLUM BACTERIODITES TO MICROBIOTA OF FIRMUCTES PHYLUM - A formulation to increase the ratio of gastrointestinal microbiota in phylum Bacteroidetes to microbiota of Firmicutes phylum preferably includes about 20-60 mg/kg of body weight of fermentable fiber, about 10-30 mg/kg of body weight of beta glucan and about 20-60 mg/kg of body weight of blueberry extracts or any fruit or berry ingredient preparation containing similar phenolics. This formulation is preferably used to control body weight, body composition, and blood glucose regulation, preferably in humans, and is preferably administered orally, preferably twice per day. | 2014-10-02 |
20140294998 | NOVEL HERBAL COMPOSITION - Disclosed herein is synergistic herbal composition comprising extracts of herbal ingredients of | 2014-10-02 |
20140294999 | NATURAL WEIGHT REDUCTION HEALTH COMPOSITION AND APPLICATION THEREOF - Health-care composition made from the combination of herbal materials and a compound with a known effect of losing weight. The herbal materials are Balsam pear and dried tangerine peel and the known for losing weight is L-carnitine L-tartrate. Such combination not only achieves a comprehensive benefficiary effect on obesity but at the same time reduced the dosage of L-carnitine L-tartrate which is relative expensive, thus reducing the cost of product significantly. | 2014-10-02 |
20140295000 | HERBAL EXTRACT PRODUCTS AND METHODS - The present invention relates to a product for topical administration in particular, a product for use in the treatment of eczema and psoriasis and other related conditions. | 2014-10-02 |
20140295001 | HERBAL/ORGANIC COMPOSITION FOR THE MANAGEMENT OF PAIN - An herbal/organic composition for the treatment and management of pain contains about 0.01 wgt % | 2014-10-02 |
20140295002 | METHODS FOR IMPROVING HEALTH IN HUMANS - Embodiments of the invention generally relate to methods and supplements for improving the health of human beings. | 2014-10-02 |
20140295003 | METHODS FOR IMPROVING HEALTH IN CANINES - A method of improving health in a canine includes administering to the canine a nutritional supplement comprising an amino acid secretagogue composition, which stimulates the pituitary gland of the canines to produce growth hormone. The nutritional supplement may be administered orally. The nutritional supplement may comprise L-arginine hydrochloride, Oxo-proline, L-lysine hydrochloride, and cysteine. When desired, the nutritional supplement may consist essentially of L-arginine hydrochloride, Oxo-proline, L-lysine hydrochloride, N-acetyl-L-cysteine, L-glutamine, and schizonepeta powder. | 2014-10-02 |
20140295004 | BIOACTIVE BOTANICAL COSMETIC COMPOSITIONS AND PROCESSES FOR THEIR PRODUCTION - The present invention is directed to bioactive botanical cosmetic compositions derived from membrane and cell serum fractions of plant cell juice. The present invention also relates to the methods for preparing these bioactive botanical cosmetic compositions and the uses of these compositions in various cosmetic formulations and as topical skin cosmetic applications. | 2014-10-02 |
20140295005 | Formulation of Curcumin With Enhanced Bioavailability of Curcumin and Method of Preparation and Treatment Thereof - Disclosure provides a formulation of curcuminoid with essential oil of turmeric to enhance the bioavailability of curcumin and to augment the biological activity of curcumin, wherein curcumin is the main constituent of curcuminoid and wherein Ar-turmerone is the main constituent of the essential oil of turmeric. An application of curcuminoid with essential oil of turmeric to enhance the bioavailability of curcumin for oral supplementation against a variety of diseases and method of doing the same is provided. | 2014-10-02 |
20140295006 | HERBAL COMPOSITION FOR TREATING METASTATIC BREAST CANCER - The invention provides a composition comprising a mixture of extracts obtained from | 2014-10-02 |
20140295007 | TOPICAL SKIN TREATMENT COMPOSITION COMPRISING DENDRANTHEMA INDICUM EXTRACT - The present invention relates to a topical skin treatment composition comprising | 2014-10-02 |
20140295008 | System and Method for Time-Release of Ellagitannins - Disclosed herein are embodiments of compositions that include a plurality of seed particles of various sizes, which may be desirable for providing the time-release of compounds present in the seed particles. By having compositions with seed particles having a range of sizes, various desirable time-release profiles may be generated by varying the range of sizes of the seed particles and varying the distribution of various sizes. | 2014-10-02 |
20140295009 | COMPOSITION AND METHOD FOR BOOSTING IMMUNOLOGICAL RESPONSE - A method for reducing inflammation at a site of injury in a mammal. A composition with an effective amount of pomegranate extract is administered to a mammal. The pomegranate extract is derived from at least one pomegranate solid and with a higher ratio of higher molecular weight polyphenols than is found in pomegranate juice substantially obtained from pomegranate arils. The effective amount is suitable to promote healing at a site of injury in said mammal. | 2014-10-02 |
20140295010 | SKIN ANTI-AGEING COMPOSITION - The invention relates to a skin anti-ageing composition. In particular a skin anti-ageing composition comprising myricetin or glycoside thereof, and at least one LXR alpha agonist. By skin ageing is meant the appearance or manifestation of any one or more of wrinkles or sagging, poor skin barrier such as dryness, scalp itch, or uneven skin tone such as age spots. | 2014-10-02 |
20140295011 | Composition Containing Triticum Aestivum Lamarck Leaf Extract or Fraction Thereof as Active Ingredient - The present invention relates to a pharmaceutical composition for prevention and treatment of hyperlipidemia or fatty liver disease, the composition containing dichloromethane fractions as an active ingredient amongst fractions obtained by fractionating the alcohol extract of | 2014-10-02 |
20140295012 | LATENT HUMAN IMMUNODEFICIENCY VIRUS REACTIVATION - Provided herein are methods or reactivating a latent Human Immunodeficiency Virus (HIV) infection in a cell. The methods comprise modulating a level of NF-fB activity in the cell by contacting the cell with an agent that produces a transient first increase in the level of NF-fB activity without a second delayed increase in NF-fB activity. Optionally, a second agent is used to prime the reactivation. Also provided herein is an isolated | 2014-10-02 |
20140295013 | APPARATUS FOR MOLDING ELECTRONIC COMPONENT - A molding apparatus for an electronic device comprises a first mold chase, a second mold chase and a middle plate which is configured to be clamped together with the electronic device between the first mold chase and second mold chase during molding. A molding cavity formed in the middle plate is configured for receiving molding compound. A package pin is mounted on the middle plate to be movable with the middle plate, and a portion of the package pin is positioned to protrude into the molding cavity to form a mark in the molding compound when molding compound is molded around the said portion of the package pin. | 2014-10-02 |
20140295014 | MOLD-TOOL SYSTEM HAVING STEM-GUIDANCE ASSEMBLY FOR GUIDING MOVEMENT OF VALVE-STEM ASSEMBLY - A mold-tool system ( | 2014-10-02 |
20140295015 | Drool shield for injection molding - The invention disclosed herein is a device to prevent damage from molten plastic to electrical wiring, heater bands and insulation of an injection molding machine. Specifically, the device consists of a flat metal disc with an aperture in the center which attaches to the distal end of the nozzle housing of an injection molding machine. When the nozzle of the injection molding machine extends through the aperture of the flat metal disc to inject molten plastic into a mold, the flat metal disc prevents molten plastic from entering the nozzle housing and damaging the electrical wiring, heater bands and insulation of the injection molding machine. | 2014-10-02 |
20140295016 | APPARATUS FOR PROCESSING PLASTIC MATERIAL - Disclosed is an apparatus for the processing of plastics, with a container with a rotatable mixing, where, in a side wall, an aperture is formed, where a conveyor is provided, with a screw rotating in a housing, wherein the imaginary continuation of the longitudinal axis of the conveyor in a direction opposite to the direction of conveying passes the axis of rotation, and wherein the ratio (V) of the active container volume (SV) to the feed volume (BV) of the container or of the cutter compactor ( | 2014-10-02 |
20140295017 | WIDE CASTING BELT, METHOD FOR MANUFACTURING A WIDE FILM, AND WIDE FILM - Disclosed is a wide casting belt, and more particularly, a wide casting belt used for manufacturing a film in a gel state by casting dope used during the manufacture of a polarizing plate for a liquid crystal display, and an optical compensation film, etc. A method for manufacturing a wide film using the wide casting belt, and a wide film manufactured with the wide casting belt are disclosed. | 2014-10-02 |
20140295018 | METHOD AND MOULDING DEVICES FOR MOULDING THREE-DIMENSIONAL PRODUCTS - The invention provides a method for moulding three-dimensional products from a mass of foodstuff starting materials which are suitable for consumption, in particular a meal mass. The method comprises the steps of filling a mould cavity, which is open on one side. with the mass of foodstuff starting materials which arc suitable for consumption. which mould cavity is defined by a boundary comprising walls and base, in order to mould a moulded three-dimensional product, and the removal of the moulded three-dimensional product from the mould cavity. In the method according to the invention, during removal the adhesion forces between the moulded product and the boundary are eliminated virtually simultaneously along all the interfaces. | 2014-10-02 |
20140295019 | INJECTION APPARATUS - This injection apparatus injects and fills the inside of a mold with a molding material, and increases the pressure. The injection apparatus is provided with a unit for a low speed step, a unit for a high speed step, a unit for a pressure increasing step, and an injection plunger. A rod of a first unit, which is any one of the three units, is mechanically coupled to the injection plunger. A rod of a second unit, which is one of the two units other than the first unit, is mechanically coupled to the first unit. A rod of a third unit, which is the unit other than the first and second units, is mechanically coupled to the second unit. | 2014-10-02 |
20140295020 | TOGGLE CLAMPING MECHANISM FOR INJECTION MOLDING MACHINE - A toggle clamping mechanism for an injection molding machine includes a toggle link, a crosshead connected to the toggle link, and a driving device for driving the crosshead. A ball spline shaft is provided parallel to a ball screw for driving the crosshead. Further, a ball spline nut provided in the crosshead is engaged with the ball spline shaft so that the crosshead may be guided by the ball spline shaft. | 2014-10-02 |
20140295021 | Scented feeder block - Scented feeder blocks for attracting game include a body at least partially formed from an edible material having a depression formed in an exterior surface, and a scent cell in the depression. The scent cell can include a stabilizer, an edible component, and a scented component. The stabilizer, the depression, or combinations thereof resist degradation of the scent cell, and the stabilizer slows dispersion of the scented component from the scent cell. Methods for forming scented feeder blocks include forming a depression in an exterior surface of a body at least partially formed from an edible material, heating a stabilizer to a first temperature such that the stabilizer melts, adding an edible component to the stabilizer, cooling the stabilizer to a second temperature less than the first and adding a scented component, and cooling the stabilizer to a third temperature less than the second such that the stabilizer solidifies. | 2014-10-02 |
20140295022 | PRALINES-IN-A-JAR - My invention, Pralines-In-A-Jar, is a fully-cooked praline candy mixture that is preserved in a jar or plastic bag. | 2014-10-02 |
20140295023 | MYCELIATED GRAIN AND OTHER MYCELIATED AGRICULTURAL MATERIALS TO BE USED AS ANIMAL FOOD SUPPLEMENT - Animal feedstuff having beneficial properties is obtained by adding to a substrate one or more fungal species of the kind that excretes substances into said substrate during its growth which are beneficial to the health, growth or weight gain of an animal, or animals to which the feedstuff is intended and allowing the fungus to grow and/or ferment on the substrate. Suitable substrates are cereal grains, residue of cereal grains, agricultural primary products, agricultural waste products, and other cellulosic materials or a combination of one or More of the same. Suitable fungus species include | 2014-10-02 |
20140295024 | FLAVOR PRE-BLENDS FOR CHEWING GUM, METHODS OF MAKING FLAVOR PRE-BLENDS AND CHEWING GUM COMPOSITIONS THEREOF - Disclosed include flavor pre-blends for use in chewing gum to impart improved chew texture and flavor release. The flavor pre-blend includes hydrophilic and lipophilic ingredients. | 2014-10-02 |
20140295025 | FILLING COMPOSITION COMPRISING HYDROLYZED WHOLE GRAIN - The present invention relates to a filling composition comprising a fat content above 20% by weight of the filling composition, a hydrolyzed whole grain composition; and an alpha-amylase or fragment thereof, which alpha-amylase or fragment thereof shows no hydrolytic activity towards dietary fibres when in the active state. | 2014-10-02 |
20140295026 | ACTIVE PLASTIC MATERIAL IN OIL - A method is provided of prolonging the shelf life of probiotic lactic-acid producing bacteria formulated in oil, by using a specific moisture absorbing technology. | 2014-10-02 |
20140295027 | Polypeptides Having Protease Activity - The present invention relates to isolated polypeptides having protease activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides in e.g. animal feed and detergents. | 2014-10-02 |
20140295028 | SCAVENGING OXYGEN - A container ( | 2014-10-02 |